Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
...
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05573802
- Locations
- 🇬🇷
General Hospital of Athens "Alexandra", NKUA, Therapeutic Clinic, Athens, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT05556798
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Hackensack Meridian Health
- Registration Number
- NCT05493618
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸Jersey Shore Medical Center, Neptune, New Jersey, United States
🇺🇸John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05461209
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇵🇱Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, Poland
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 78
- Registration Number
- NCT05393024
- Locations
- 🇮🇹
AOU Ospedali Riuniti Umberto I, Ancona, Italy
🇮🇹A.O.U. Arcispedale Sant'Anna, Ferrara, Italy
🇮🇹A.O.U. Federico II, Napoli, Italy
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 170
- Registration Number
- NCT05297240
- Locations
- 🇪🇸
H. General Elche, Elche, Spain
🇪🇸H. Cruces, Bilbao, Spain
🇪🇸H. Doctor José Molina Orosa, Arrecife, Spain
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05280275
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
🇬🇷Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA), Athens, Greece
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 1
- Registration Number
- NCT05117008
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT05091372
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 177
- Registration Number
- NCT05064358
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.